Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

This study has been completed.
Sponsor:
Information provided by:
Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01273935
First received: January 10, 2011
Last updated: NA
Last verified: January 2010
History: No changes posted

January 10, 2011
January 10, 2011
January 2010
Not Provided
Result of platelet function test [ Designated as safety issue: No ]
Aggregometry result of antiplatelet therapy
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

The aim of this study is to evaluate the low-response prevalence of early antiplatelet therapy and to test the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).

Antiplatelet agents are important therapeutic options in treating patients with acute ischemic strokes to prevent recurrent ischemic events or death. The aim of this study was to evaluate the low-response prevalence of early antiplatelet therapy and the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients admitted to the stroke unit

Test the Efficacy of Antiplatelet Regimes in Acute Stroke
Not Provided
  • Responder
    Responder versus Non-Responder as a result of platelet function test
  • Non-Responder
    According to the result of platelet function test
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
December 2010
Not Provided

Inclusion Criteria:

  • suspected acute cerebrovascular ischemic events and patients who were admitted to the stroke unit where antiplatelet therapy was initiated

Exclusion Criteria:

  • severe liver disorders, current gastrointestinal disorders, congestive heart failure, life-threatening malignancies and a personal or family history of bleeding disorders
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01273935
MevesASS01
No
Medical Faculty Ruhr-University Bochum, Dekanat der Medizinischen Fakultät, Forschungsreferat - FoRUM
Ruhr University of Bochum
Not Provided
Principal Investigator: Saskia H Meves, MD Department of Neurology, St. Josef - Hospital, Bochum, Germany
Ruhr University of Bochum
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP